EXHIBIT
99.1
Intellipharmaceutics to present at the 9th Annual LD Micro
Invitational
Toronto, Ontario, May 29, 2019, Intellipharmaceutics International
Inc. (OTCQB: IPCIF and TSX:IPCI) ("Intellipharmaceutics" or
the "Company"), a pharmaceutical company specializing in the
research, development and manufacture of novel and generic
controlled-release and targeted-release oral solid dosage drugs,
announced today that it will be presenting at the 9th annual LD Micro
Invitational on Tuesday June 4th, 2019 at 2:20pm
PST. Executive Greg Powell, CFO will be presenting and meeting with
investors.
About Intellipharmaceutics
Intellipharmaceutics International
Inc. is a pharmaceutical company specializing in the research,
development and manufacture of novel and generic controlled-release
and targeted-release oral solid dosage drugs. The Company's
patented Hypermatrix™
technology is a multidimensional controlled-release drug delivery
platform that can be applied to a wide range of existing and new
pharmaceuticals. Intellipharmaceutics has developed several drug
delivery systems based on this technology platform, with a pipeline
of products (some of which have received FDA approval) in various
stages of development. The Company has ANDA and NDA 505(b)(2) drug
product candidates in its development pipeline. These include the
Company’s abuse-deterrent
oxycodone hydrochloride extended release formulation
(“Oxycodone ER”) based on its proprietary
nPODDDS™ novel Point Of
Divergence Drug Delivery System (for which an NDA has been filed
with the FDA), and Regabatin™ XR (pregabalin extended-release
capsules).
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into
several influential events annually (Invitational, Summit, and Main
Event).
In 2015, LDM launched the first pure microcap index (the LDMi) to
exclusively provide intraday information on the entire sector. LD
will continue to provide valuable tools for the benefit of everyone
in the small and micro-cap universe.
"This year’s Invitational will showcase some of the most
unique names in the financial world, from early-stage start-ups to
well-established names on the national exchanges” stated
Chris Lahiji, while waiting in the longest TSA line in history.
“Even though LD has emerged as one of the largest and most
influential organizations in the space, our focus has never
deviated from showcasing some of the more interesting businesses in
the world to our ever-growing community.”
For those interested in attending, please contact David Scher
at david@ldmicro.com
or visit www.ldmicro.com
for more
information.
Cautionary Statement Regarding Forward-Looking
Information
Certain statements in this document
constitute “forward-looking statements” within the
meaning of the United States Private Securities Litigation Reform
Act of 1995 and/or “forward-looking information” under
the Securities Act (Ontario). These statements
include, without limitation, statements expressed or implied
regarding our expectations regarding our plans, goals and
milestones, status of developments or expenditures relating to our
business, plans to fund our current activities, and statements
concerning our partnering activities, health regulatory
submissions, strategy, future operations, future financial
position, future sales, revenues and profitability, projected costs
and market penetration and risks or uncertainties related to our
ability to comply with OTCQB and TSX
requirements. In some cases,
you can identify forward-looking statements by terminology such as
“appear”, “unlikely”, “target”,
"may", "will", "should", "expects", "plans", "plans to",
"anticipates", "believes", "estimates", "predicts", "confident",
"prospects", "potential", "continue", "intends", "look forward",
"could", “would”, “projected”,
“goals”, “set to”, “seeking” or
the negative of such terms or other comparable terminology. We made
a number of assumptions in the preparation of our forward-looking
statements. You should not place undue reliance on our
forward-looking statements, which are subject to a multitude of
known and unknown risks and uncertainties that could cause actual
results, future circumstances or events to differ materially from
those stated in or implied by the forward-looking statements. Risks
and uncertainties relating to us and our business can be found in
the "Risk Factors" section of our latest annual information form,
our latest Form 20-F, and our latest Form F-1 and Form F-3
registration statements (including any documents forming a part
thereof or incorporated by reference therein), as amended, as well
as in our reports, public disclosure documents and other filings
with the securities commissions and other regulatory bodies in
Canada and the U.S., which are available on www.sedar.com and
www.sec.gov. The forward-looking statements reflect our current
views with respect to future events and are based on what we
believe are reasonable assumptions as of the date of this document
and we disclaim any intention and have no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Trademarks used herein are the property of their respective
holders.
Unless the context otherwise requires, all references to "we,"
"us," "our," "Intellipharmaceutics," and the "Company" refer to
Intellipharmaceutics International Inc. and its
subsidiaries.
CONTACT INFORMATION
Company
Contact:
Intellipharmaceutics
International Inc.
Greg
Powell
Chief
Financial Officer
416.798.3001
ext. 106
investors@intellipharmaceutics.com
Investor
Contact:
PCG
Advisory
Kirin
Smith
646.863.6519
ksmith@pcgadvisory.com